Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data
Srđan Verstovšek(Unknown), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Patrick Trojer(Morpho (United States)), Gozde Colak(Morpho (United States)), Pietro Taverna, Jike Cui(Morpho (United States)), Patricia J. Keller(Constellation Pharmaceuticals (United States)), Horatiu Olteanu(Mayo Clinic in Arizona), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Natalia Curto‐García(Guy's and St Thomas' NHS Foundation Trust), Sergey Efuni(Oncoceutics (United States)), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Chen Dong(Mayo Clinic in Arizona), April Chiu(Mayo Clinic), John Mascarenhas(Tisch Hospital), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Zehua Chen(Sun Yat-sen University), Curtis A. Hanson(Mayo Clinic in Arizona), Stephen T. Oh(Washington University in St. Louis), Oksana Zavidij(Constellation Pharmaceuticals (United States)), Moshe Talpaz(University of Michigan)
Cited by 9
Related Papers
Full-length transcriptome assembly from RNA-Seq data without a reference genome
|Nature Biotechnology|2011|22.7k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k